Antifungal Pharmacokinetics and Pharmacodynamics

被引:85
|
作者
Lepak, Alexander J. [1 ]
Andes, David R. [1 ]
机构
[1] Univ Wisconsin, Madison, WI 53705 USA
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2015年 / 5卷 / 05期
关键词
INVASIVE PULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; IN-VITRO MODEL; GUINEA-PIG MODEL; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; GALACTOMANNAN ENZYME-IMMUNOASSAY; NEUTROPENIC MURINE MODEL; DOSE-DEPENDENT ACTIVITY; COMBINATION THERAPY; LIPID COMPLEX;
D O I
10.1101/cshperspect.a019653
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Antifungal PK/PD Considerations in Fungal Pulmonary Infections
    Lepak, Alexander J.
    Andes, David R.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (06) : 783 - 794
  • [32] A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model
    Wang, Taotao
    Zhang, Tao
    Meng, Ti
    Li, Ying
    Chen, Lu
    Yang, Qianting
    Dong, Haiyan
    Lei, Jin'e
    Chen, Limei
    Dong, Yalin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [33] Echinocandin pharmacodynamics: review and clinical implications
    Pound, Melanie W.
    Townsend, Mary L.
    Drew, Richard H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (06) : 1108 - 1118
  • [34] Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
    Romuald Bellmann
    Piotr Smuszkiewicz
    Infection, 2017, 45 : 737 - 779
  • [35] Antifungal drugs: An updated review of central nervous system pharmacokinetics
    Wirth, Fernanda
    Ishida, Kelly
    MYCOSES, 2020, 63 (10) : 1047 - 1059
  • [36] Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs
    Ueno, Koichi
    Sato, Hiromi
    HYPERTENSION RESEARCH, 2012, 35 (03) : 245 - 250
  • [37] Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants
    Roberts, Jessica K.
    Stockmann, Chris
    Constance, Jonathan E.
    Stiers, Justin
    Spigarelli, Michael G.
    Ward, Robert M.
    Sherwin, Catherine M. T.
    CLINICAL PHARMACOKINETICS, 2014, 53 (07) : 581 - 610
  • [38] Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections
    Kuti, Effie L.
    Kuti, Joseph L.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (10) : 1287 - 1300
  • [39] Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
    Podany, Anthony T.
    Scarsi, Kimberly K.
    Fletcher, Courtney V.
    CLINICAL PHARMACOKINETICS, 2017, 56 (01) : 25 - 40
  • [40] Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
    Tsesmetzis, Nikolaos
    Paulin, Cynthia B. J.
    Rudd, Sean G.
    Herold, Nikolas
    CANCERS, 2018, 10 (07)